The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma

N. Asano; T. Yamakazi; M. Seto; A. Matsumine; H. Yoshikawa; A. Uchida

doi:10.1302/0301-620X.86B4.14484

Article alerts Social media

Current issue

Research

The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma

N. Asano
T. Yamakazi
M. Seto
A. Matsumine
H. Yoshikawa
A. Uchida

Download PDF

The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma

Asano N, Yamakazi T, Seto M, Matsumine A, Yoshikawa H, Uchida A. The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma. J Bone Joint Surg Br. 2004;86-B(4):607-612. doi:10.1302/0301-620X.86B4.14484

Asano, N., et al. “The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma.” The Journal of Bone & Joint Surgery British Volume, vol. 86-B, no. 4, 2004, pp. 607-612., https://doi.org/10.1302/0301-620X.86B4.14484

Asano, N., Yamakazi, T., Seto, M., Matsumine, A., Yoshikawa, H., & Uchida, A. (2004). The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma. The Journal of Bone & Joint Surgery British Volume, 86-B(4), 607-612. https://doi.org/10.1302/0301-620X.86B4.14484

Asano, N., Yamakazi, T., Seto, M., Matsumine, A., Yoshikawa, H. and Uchida, A. (2004) “The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma.” The Journal of Bone & Joint Surgery British Volume, 86-B(4), pp. 607-612. Available at: https://doi.org/10.1302/0301-620X.86B4.14484

Asano, N., T. Yamakazi, M. Seto, A. Matsumine, H. Yoshikawa, and A. Uchida. “The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma.” The Journal of Bone & Joint Surgery British Volume 86-B, no. 4 (2004): 607-612. https://doi.org/10.1302/0301-620X.86B4.14484

Copy to clipboard

BibTeX

EndNote

RIS

Abstract

We investigated the rates of expression of bone morphogenetic protein-2 (BMP-2) in 29 adult patients with high-grade malignant fibrous histiocytoma of soft tissue, using the BMP-2-specific monoclonal antibody, AbH3b2/17, and found that they ranged from 1.9% to 78.9%. The survival at five years of the groups expressing high (≥30%) and low (< 30%) levels of BMP-2 was 85.7% and 36.3%, respectively. Multivariable analysis showed that only BMP-2 had prognostic significance for continuous disease-free survival and for overall survival (p < 0.05). Our findings indicate that over-expression of BMP-2 in malignant fibrous histiocytoma of soft tissue is the most reliable prognostic indicator of the parameters assessed.

Correspondence should be sent to Dr N. Asano.

For access options please click here

Figure 1

Some description here